Silence Therapeutics (SLN) Enterprise Value (2018 - 2026)

Silence Therapeutics has disclosed Enterprise Value across 9 years of filings, most recently posting -$70.1 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$70.1 million, up 48.67% year-over-year; the trailing twelve-month figure through Mar 2026 was -$70.1 million (up 48.67% YoY), and the FY2025 annual result was -$85.1 million, up 54.26% from the prior year.
• Enterprise Value came in at -$70.1 million for Q1 2026 at Silence Therapeutics, up from -$85.1 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$49.2 million in Q4 2022 to a low of -$186.1 million in Q4 2024.
• The 5-year median for Enterprise Value is -$93.7 million (2025), against an average of -$101.4 million.
• Across the five-year window, Enterprise Value tumbled 173.67% in 2024 and soared 54.26% in 2025, its largest moves.
• Silence Therapeutics' Enterprise Value stood at -$49.2 million in 2022, then sank by 38.06% to -$68.0 million in 2023, then sank by 173.67% to -$186.1 million in 2024, then jumped by 54.26% to -$85.1 million in 2025, then rose by 17.67% to -$70.1 million in 2026.
• The last three Enterprise Value figures came in at -$70.1 million (Q1 2026), -$85.1 million (Q4 2025), and -$102.2 million (Q3 2025), per Business Quant data.